Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy

A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastatic breast cancer patients are refractory to Her2-targeted trastuzumab-like therapy. Some of this resistance has been attributed to the upregulation of immune checkpoints such as programmed cell death-1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Mittal, Deepak, Vijayan, Dipti, Neijssen, Joost, Kreijtz, Joost, Habraken, Maurice M. J. M., Van Eenennaam, Hans, Van Elsas, Andrea, Smyth, Mark J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6791437/
https://ncbi.nlm.nih.gov/pubmed/31646095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1648171
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller